Across the recent three months, 16 analysts have shared their insights on UnitedHealth Group UNH, expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 11 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 4 | 7 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $631.94, a high estimate of $675.00, and a low estimate of $595.00. This upward trend is apparent, with the current average reflecting a 1.42% increase from the previous average price target of $623.07.
Breaking Down Analyst Ratings: A Detailed Examination
A comprehensive examination of how financial experts perceive UnitedHealth Group is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jessica Tassan | Piper Sandler | Lowers | Overweight | $600.00 | $605.00 |
| Michael Wiederhorn | Oppenheimer | Raises | Outperform | $640.00 | $610.00 |
| Scott Fidel | Stephens & Co. | Raises | Overweight | $675.00 | $605.00 |
| George Hill | Deutsche Bank | Raises | Buy | $625.00 | $595.00 |
| Andrew Mok | Barclays | Raises | Overweight | $655.00 | $603.00 |
| Andrew Mok | Barclays | Lowers | Overweight | $603.00 | $604.00 |
| Gary Taylor | TD Cowen | Raises | Buy | $609.00 | $601.00 |
| Kevin Caliendo | UBS | Lowers | Buy | $650.00 | $680.00 |
| Scott Fidel | Stephens & Co. | Lowers | Overweight | $605.00 | $632.00 |
| Sarah James | Cantor Fitzgerald | Raises | Overweight | $644.00 | $591.00 |
| David Macdonald | Truist Securities | Lowers | Buy | $625.00 | $640.00 |
| Ben Hendrix | RBC Capital | Lowers | Outperform | $595.00 | $615.00 |
| Matthew Gillmor | Keybanc | Lowers | Overweight | $650.00 | $675.00 |
| Ricky Goldwasser | Morgan Stanley | Lowers | Overweight | $610.00 | $615.00 |
| Kevin Fischbeck | B of A Securities | Lowers | Buy | $650.00 | $675.00 |
| Matthew Gillmor | Keybanc | Announces | Overweight | $675.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to UnitedHealth Group. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of UnitedHealth Group compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
For valuable insights into UnitedHealth Group's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on UnitedHealth Group analyst ratings.
All You Need to Know About UnitedHealth Group
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Unraveling the Financial Story of UnitedHealth Group
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: UnitedHealth Group displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 8.55%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: UnitedHealth Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.11%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.59%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): UnitedHealth Group's ROA excels beyond industry benchmarks, reaching 2.07%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 0.83, UnitedHealth Group faces challenges in effectively managing its debt levels, indicating potential financial strain.
Analyst Ratings: Simplified
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
